Increasing burden of multiple long-term conditions and mortality risk following COVID-19 diagnosis: a national cohort study of one million adults with cardiovascular disease in England.
Yogini V Chudasama, Sharmin Shabnam, Kamlesh Khunti, Cameron Razieh, Clare L Gillies, Nazrul Islam, Thomas Yates, Amitava Banerjee, Nathalie Conrad, Spiros Denaxas, Claire Lawson, Francesco Zaccardi
{"title":"Increasing burden of multiple long-term conditions and mortality risk following COVID-19 diagnosis: a national cohort study of one million adults with cardiovascular disease in England.","authors":"Yogini V Chudasama, Sharmin Shabnam, Kamlesh Khunti, Cameron Razieh, Clare L Gillies, Nazrul Islam, Thomas Yates, Amitava Banerjee, Nathalie Conrad, Spiros Denaxas, Claire Lawson, Francesco Zaccardi","doi":"10.1093/pubmed/fdag062","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Individuals with cardiovascular disease (CVD) experienced high mortality during coronavirus disease 2019 (COVID-19), yet most live with multiple long-term conditions (MLTCs). We examined the association between MLTCs burden and mortality following COVID-19 among people with CVD.</p><p><strong>Methods: </strong>In this population-based cohort study, linked national electronic health records from England were analysed. Adults aged ≥18 years with CVD and a positive COVID-19 test between 31 January 2020 and 31 October 2022 were included. MLTCs burden was defined as the number of additional long-term conditions beyond CVD (0, 1, 2, or ≥3). One-year mortality was assessed using adjusted flexible parametric Royston-Parmar models.</p><p><strong>Results: </strong>In 1 081 695 individuals with CVD and COVID-19, 89.7% had at least one long-term condition (LTC) and 67.9% had two or more. Increasing MLTC burden showed a dose-response association with mortality. Compared to individuals without additional LTCs, mortality risk was doubled for those with one LTC (adjusted hazard ratio: 1.86, 95% CI: 1.76-1.96), tripled among those with two LTCs (3.00, 2.85-3.16), and five-fold higher in those with ≥3 LTCs (5.00, 4.75-5.27). Associations were consistent across CVD subtypes.</p><p><strong>Conclusions: </strong>MLTCs burden was a stronger determinant of mortality risk than CVD subtype alone. Findings support moving beyond single-disease models towards integrated, MLTC-informed care, and pandemic preparedness.</p>","PeriodicalId":94107,"journal":{"name":"Journal of public health (Oxford, England)","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of public health (Oxford, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/pubmed/fdag062","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Individuals with cardiovascular disease (CVD) experienced high mortality during coronavirus disease 2019 (COVID-19), yet most live with multiple long-term conditions (MLTCs). We examined the association between MLTCs burden and mortality following COVID-19 among people with CVD.
Methods: In this population-based cohort study, linked national electronic health records from England were analysed. Adults aged ≥18 years with CVD and a positive COVID-19 test between 31 January 2020 and 31 October 2022 were included. MLTCs burden was defined as the number of additional long-term conditions beyond CVD (0, 1, 2, or ≥3). One-year mortality was assessed using adjusted flexible parametric Royston-Parmar models.
Results: In 1 081 695 individuals with CVD and COVID-19, 89.7% had at least one long-term condition (LTC) and 67.9% had two or more. Increasing MLTC burden showed a dose-response association with mortality. Compared to individuals without additional LTCs, mortality risk was doubled for those with one LTC (adjusted hazard ratio: 1.86, 95% CI: 1.76-1.96), tripled among those with two LTCs (3.00, 2.85-3.16), and five-fold higher in those with ≥3 LTCs (5.00, 4.75-5.27). Associations were consistent across CVD subtypes.
Conclusions: MLTCs burden was a stronger determinant of mortality risk than CVD subtype alone. Findings support moving beyond single-disease models towards integrated, MLTC-informed care, and pandemic preparedness.